Johnson & Johnson $JNJ Shares Sold by Midland Wealth Advisors LLC

Midland Wealth Advisors LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 14.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 13,921 shares of the company’s stock after selling 2,311 shares during the period. Midland Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,126,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. GFG Capital LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at about $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter worth $52,000. Finally, Pandora Wealth Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at $65,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.3%

JNJ stock opened at $186.50 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market cap of $449.34 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The company has a fifty day moving average price of $184.25 and a 200 day moving average price of $168.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Raymond James Financial boosted their target price on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Argus set a $210.00 price objective on Johnson & Johnson in a research report on Wednesday, October 15th. Citigroup boosted their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. Finally, Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.